Muscle Invasive Bladder Cancer Mibc clinical trials

Explore recruiting muscle invasive bladder cancer mibc clinical trials.

Recruiting muscle invasive bladder cancer mibc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Muscle Invasive Bladder Cancer Mibc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib (ERDA) and cetrelimab (CET) combination as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations (SOGUG-NEOWIN)

Italy, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized Phase III Study to Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants with Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy

Austria, Czechia, France, Germany, Spain, Portugal +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC) (KEYNOTE-992)

Netherlands, Spain, Romania, Poland, Latvia, Czechia +5 more

Phase III and phase IV (Integrated) EU CTIS Study details

PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF E-VIM VACCINE CVX1 WITH OR WITHOUT ICI IN THE TREATMENT OF SUBJECTS WITH MUSCLE INVASIVE BLADDER CANCER (MIBC) OR LOCALIZED OR LOCALLY ADVANCED RENAL CELL CANCER (RCC).

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Muscle Invasive Bladder Cancer Mibc trials by city

Muscle Invasive Bladder Cancer Mibc in Toronto Muscle Invasive Bladder Cancer Mibc in Vancouver Muscle Invasive Bladder Cancer Mibc in Montreal Muscle Invasive Bladder Cancer Mibc in Calgary Muscle Invasive Bladder Cancer Mibc in Edmonton Muscle Invasive Bladder Cancer Mibc in Ottawa Muscle Invasive Bladder Cancer Mibc in Winnipeg Muscle Invasive Bladder Cancer Mibc in Quebec City Muscle Invasive Bladder Cancer Mibc in Hamilton Muscle Invasive Bladder Cancer Mibc in Kitchener Muscle Invasive Bladder Cancer Mibc in London Muscle Invasive Bladder Cancer Mibc in Halifax Muscle Invasive Bladder Cancer Mibc in New York Muscle Invasive Bladder Cancer Mibc in Los Angeles Muscle Invasive Bladder Cancer Mibc in Chicago Muscle Invasive Bladder Cancer Mibc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease